Interestingly, recent studies have identified xCT as a key regulator of cancer cell metabolic reprogramming and therapeutic target in gastric cancer and in triple-negative breast carcinomas.32, 33 In this study, we explored the utility of small-molecule inhibitors of xCT as antiglioma agents. This evidence concerns the gene SLC7A11 and cancer.